Home / Clinics / Peptide Therapy
Open a Peptide Therapy Clinic While the Market Is Still Wide Open.
Peptide searches have now surpassed Ozempic in U.S. volume. 10.1 million monthly searches. A $163.98B global market in 2026. Sermorelin, BPC-157, and the rest of the protocol-aware compound landscape are now mainstream search terms — and the compliant, well-structured clinic to serve them barely exists in most U.S. markets.
Book a Strategy CallWhat the Numbers Actually Show
Peptide-related searches reached 10.1 million monthly in the U.S. as of January 2026. "Cost of peptide therapy" is up 300% year over year. Peptide searches have now surpassed Ozempic in U.S. search volume — a documented category shift, not a trend cycle. The global peptide therapeutics market reached $163.98 billion in 2026 and is projected to reach $294.58 billion by 2033.
This is not early-adopter noise. This is mainstream consumer demand arriving at a market where compliant, well-structured local clinics are still rare. The entrepreneur who opens the first credible peptide clinic in their market captures share that takes years to displace.
The gap is real: demand is massive, but setting up a compliant, well-structured peptide clinic is genuinely complex. Most operators try to enter without the compliance structure, supplier relationships, or patient acquisition infrastructure. First clinic in a market with all three right wins.
Source: SEMrush, January 2026. Local demand varies by market.
What a Peptide Therapy Clinic Actually Offers Patients
The service menu spans eight clinical categories — each with documented patient demand and specific compounds that capture search traffic at the compound level.
BPC-157 for gut repair, tissue regeneration, and joint recovery. TB-500 (Thymosin Beta-4) for wound healing, inflammation, and athletic recovery.
Sermorelin and CJC-1295 for growth hormone optimization. Epithalon for telomere-linked protocols. GHK-Cu (copper peptide) for skin and cellular regeneration.
AOD-9604 for metabolic support and lipolysis. MOTS-c for mitochondrial function. Peptide-based protocols complement clinical weight programs — for GLP-1 specifically, see our Metabolic Weight Loss page.
Ipamorelin — selective GHRP for growth hormone release and muscle recovery. BPC-157 and TB-500 for injury healing and performance maintenance.
Thymosin Alpha-1 for immune modulation. A protocol category with strong patient interest and limited local clinical supply.
Selank and Semax — Russian-developed nootropic peptides for cognitive performance, focus, and mood support. A fast-growing compound category with low local supply.
PT-141 (bremelanotide) for libido and sexual function in both men and women. Pairs with broader sexual wellness offerings — see our Sexual Wellness clinic page for the full standalone model.
BPC-157 and select compounds applied for neurological context — neuroprotection, neuroinflammation, and cognitive health. For the full neurological wellness clinic model with HBOT and exosomes, see our Neurological Wellness page.
Peptide Compliance: What Most Operators Underestimate
The peptide space operates within an FDA regulatory framework most first-time operators do not fully understand before entering. The 503A compounding pharmacy structure, the distinction between Category 1 and Category 2 compounds, state-by-state prescribing variation, and the Medical Director relationship for a peptide practice all require navigation before the first patient walks in.
ACG navigates the current regulatory environment with you. Paid advertising for peptide clinics is restricted on major platforms — organic SEO is the primary patient acquisition channel for this category. ACG builds that infrastructure as part of the setup.
This section is where ACG separates from every generic consultant. We have launched peptide programs across hundreds of clinics. The compliance framework, pharmacy relationships, and patient acquisition infrastructure are already built.
ACG connects clients to pre-vetted 503A compounding pharmacy partners — the legal framework for individualized compound prescriptions.
FDA classification framework navigated as part of ACG's setup — which compounds require which structures, and what that means for your clinic.
Prescribing authority and scope-of-practice requirements vary significantly by state. ACG maps this for your specific location.
The MD relationship for a peptide practice has specific oversight requirements. ACG introduces clients to vetted physicians across 46 states.
Because paid platforms restrict peptide content, organic search is the primary acquisition channel. ACG builds this from day one.
Why Peptide Patients Become Long-Term Clients
Peptide protocols run 3 to 12 months. Patients who see results stay and refer. The clinic that earns patient trust in this category does not compete on price — it competes on outcomes and relationship.
One fee. One engagement. Everything included. No upsells, no ongoing royalties, no franchise dependency. You own the clinic, the brand, and the equity.
3–12 Months
Per patient per protocol — creating predictable recurring revenue from day one.
Required
ACG coordinates the clinical infrastructure. You own and operate the business.
Launched
Across 46 states. Including peptide programs from the category's earliest days.
Launch Window
From keys received, market and regulatory conditions permitting.
Your Market May Already Be
Waiting for This Clinic.
Book a free 30-minute strategy call. ACG will walk you through the peptide therapy opportunity in your specific market — the compliance picture, the compound access, and what the process looks like from first conversation to open doors.
Book a Strategy CallFree 30-minute call · No pitch · ACG works with a select number of clients at any given time